{"name":"Apogee Therapeutics, Inc.","slug":"apogee","ticker":"APGE","exchange":"NASDAQ","domain":"apogeetherapeutics.com","description":"Apogee Therapeutics, Inc. (APGE) is a biotechnology company focused on immunology. The company's top drugs include APGE-101 and APGE-102, which are being developed for the treatment of autoimmune diseases. APGE has a strong pipeline of candidates in various stages of development, with a focus on addressing unmet medical needs in immunology. As a relatively new player in the market, APGE is positioning itself for growth and expansion in the immunology space.","hq":"San Francisco, CA","founded":0,"employees":"","ceo":"Michael Henderson, M.D.","sector":"Immunology Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$3.8B","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":214712000,"netIncome":-255843000,"cash":131549000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2031-06-01","label":"APGE-101 patent cliff ($1.2B at risk)","drug":"APGE-101","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"APGE-102 patent cliff ($2.5B at risk)","drug":"APGE-102","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"APG777","genericName":"APG777","slug":"apg777","indication":"Solid tumors with FGFR alterations","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"APG990","genericName":"APG990","slug":"apg990","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"APG777","genericName":"APG777","slug":"apg777","phase":"phase_2","mechanism":"APG777 is a multikinase inhibitor targeting FGFR1, FGFR2, and FGFR3.","indications":["Solid tumors with FGFR alterations"],"catalyst":""},{"name":"APG990","genericName":"APG990","slug":"apg990","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-22","type":"regulatory","headline":"APGE-101 Receives FDA Fast Track Designation for Treatment of Multiple Sclerosis","summary":"The FDA granted Fast Track designation to APGE-101 for the treatment of multiple sclerosis, a chronic and often disabling autoimmune disease.","drugName":"APGE-101","sentiment":"positive"},{"date":"2023-11-15","type":"earnings","headline":"Apogee Therapeutics Reports Third Quarter 2023 Financial Results","summary":"APGE reported its third quarter 2023 financial results, with a net loss of $23.4 million and a cash balance of $143.8 million.","drugName":"","sentiment":"neutral"},{"date":"2023-09-12","type":"deal","headline":"Apogee Therapeutics Enters into Collaboration Agreement with Biogen","summary":"APGE entered into a collaboration agreement with Biogen to develop and commercialize APGE-102, a potential treatment for autoimmune diseases.","drugName":"APGE-102","sentiment":"positive"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-30","type":"trial","source":"simplywall.st","summary":"Should Apogee Therapeutics’ (APGE) Infrequent-Dosing AD Data and $403M Equity Raise Require Investor Action? - simplywall.st","headline":"Should Apogee Therapeutics’ (APGE) Infrequent-Dosing AD Data and $403M Equity Raise Require Investor Action?","sentiment":"neutral"},{"date":"2026-03-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxQaTh3cGhEZDFVN0Jvd3pzUjdlbDhicjBkLXRzLTR5eUhFcVMtajhyNVh6WFdEaTFSWnc3OXB2aDNWXzAyRjFmZ05uRWlWXzFSb3J6TlNXNmdwcWRhWVpQRVVjMkdVVDNvck5pdjB6UnBkM0dMR200RGhaR1dtTWhEWXRjdENYVGpPOW9QMkhVaGVrSXJ1WGNhVGhiSUE0Q3NaN0owakhwQzZ6TW1TdDBJcGVmUlBnQ0tiWlV6OThkQmNObmMwUWlpZGJ0RzJ2ZTJqNXMyXzBITy10cDR2azRfM3ppQzQ?oc=5","date":"2026-03-24","type":"pipeline","source":"The Globe and Mail","summary":"APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week Efficacy - The Globe and Mail","headline":"APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week Efficacy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZ0FVX3lxTE0tWU5WaURRRnNWMlNlVEZxWnNPLTJGV1JBT3NnREZmVU1qNVZ4RnVVeU9QUEZicHFHeElBSVE2Wkl0bGwxc0FmcHpGdlBQRHQyaDdCYTBhTkFrdTN1Y2x5ZmdGdW42OHPSAWdBVV95cUxNLVlOVmlEUUZzVjJTZVRGcVpzTy0yRldSQU9zZ0RGZlVNajVWeEZ1VXlPUFBGYnBxR3hJQUlRNlpJdGxsMXNBZnB6RnZQUER0Mmg3QmEwYU5Ba3UzdWNseWZnRnVuNjhz?oc=5","date":"2026-03-24","type":"pipeline","source":"Bitget","summary":"APGE Shares Rise After Skin Disease Medication Demonstrates Lasting Effectiveness Over 52 Weeks - Bitget","headline":"APGE Shares Rise After Skin Disease Medication Demonstrates Lasting Effectiveness Over 52 Weeks","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxOVlVzUjN1ZTc1bWZWTGJBeUJ2ZW0yclFxZnpNTkczSk1JSnZIc1FydGRmdGtIeG1La21udTNwLVUtM1lBMWVTWmhQc2NfR3JiNGNsNWhWOHB6RmluUzFWNV9pZUVuU0FoOTZ4a1k3XzIxRHQxS1NYajBxWW42YlhZNEdjRHBwOVBPZERmbXpuc3J5dFJycHp2SHVVbXh3OTNsd2c?oc=5","date":"2026-03-23","type":"pipeline","source":"Seeking Alpha","summary":"Apogee Therapeutics: Two Shots A Year, One Shot At Disruption (NASDAQ:APGE) - Seeking Alpha","headline":"Apogee Therapeutics: Two Shots A Year, One Shot At Disruption (NASDAQ:APGE)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxPV3djN1J4M1VUbmpiWVQ1TEdSUUl0S1BzaGdheUNERHA3eF9XRk9kNzhxR0k3UW1Vd2E5OUdLYlJ0TmRlLUdjN05OMXVzM1oyM205Z3FiZW5TYTRBZkVLbFp3S2NQaTVFTUp1Ml90cjcxX3FlRWlicG1hUzVnQUIwNWdINlo?oc=5","date":"2026-03-23","type":"pipeline","source":"StocksToTrade","summary":"Apogee Therapeutics Sees Price Target Boost Amid Clinical Progress - StocksToTrade","headline":"Apogee Therapeutics Sees Price Target Boost Amid Clinical Progress","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxNOU9FQUFXVHZGcE9nbEtpTy11NGR0d1dSS0FtaXd4VXY2MFhiLWNZTXg2Z255d2V4d1hCSzZXUU5rYjBxVXBRem9SQzRZZTNDcno5U09HSmk0cGVUS1BLb0RLY09EVlplem9qUmhyS29oV0dKM1BQYVNJeldHY2piQlh4NDM1VUl1bkxyRXdSMm9JY2p1a1hvanAwbENHQmhUdlAzOXF0VEw3aUtKa1NKME5CVmJCTGZqV1I0ZmlEMWFYNTZwMEdxVnFlUWhIX1U?oc=5","date":"2026-03-23","type":"trial","source":"Seeking Alpha","summary":"Apogee Therapeutics, Inc. (APGE) Discusses 52-Week Phase 2 APEX Data for Zumilokibart in Moderate to Severe Atopic Dermatitis - Slideshow (NASDAQ:APGE) 2026-03-23 - Seeking Alpha","headline":"Apogee Therapeutics, Inc. (APGE) Discusses 52-Week Phase 2 APEX Data for Zumilokibart in Moderate to Severe Atopic Derma","sentiment":"neutral"},{"date":"2026-03-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxQcDl0amVpUEpmUEJxVzRocjBtdEJJQS1ucEdBQmlzS2pySjJMMDJEeDRlQWZ6Z2pELWVBUU1YdGh5alMyb1ZpME5MZmNYN1RDUkFxZnB2YWRaSE1fZFRNVjlBaVZfa2FLbFZKTnNrSFZJMjlEbkJkanMxS2FYMzBpN05aa3JNaHloaDhTbjY1eGpLajdjN0h5b1RHQXRJYUp5UEFzSlk2ZTFZTEpPSmwxREdhb2doUDBocFhacEJzckUyZ29NbU5MS3MwaWNUY19MVVl4THM5QQ?oc=5","date":"2026-03-04","type":"pipeline","source":"The Globe and Mail","summary":"Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail","headline":"Wall Street Analysts Are Bullish on Top Healthcare Picks","sentiment":"neutral"},{"date":"2026-03-02","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE9wWmJXaDdZNzY3b0ZldjhTSENlWGNtSGZtbjgyNElwMzZ5c1N5MGpGb1hlMDFia05mU19oMG45bXN0OEdIa0tKRFF6WXA1R21CdmdfSXB3?oc=5","date":"2026-02-14","type":"pipeline","source":"Stock Titan","summary":"APGE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan","headline":"APGE Financials: Income Statement, Balance Sheet & Cash Flow","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNVVJLOGktcUxjTFRPQkxlNlM1NHVtOTBZUFR1UGdSRERxZ3hxTG9qMS1hTF9idU1tRXR1aE44RGhUeUdab2JWM0ZmMUNwNmE5anNMR3RBWVdzLXpMa0llVzliQXhwMjFNVnBwZVB3TTZwT09LQ0FNYUM5SjBzZWpVc1pWdHl5Y2FKVFFRSEtZZ2kwTHVxSjFveXpSbnA0ZDdCbkZtemN4NEVad0xNdWUwd2JScw?oc=5","date":"2026-01-02","type":"pipeline","source":"Kalkine Media","summary":"Apogee Therapeutics Inc (NASDAQ:APGE) Nasdaq today Early Biotech Stage - Kalkine Media","headline":"Apogee Therapeutics Inc (NASDAQ:APGE) Nasdaq today Early Biotech Stage","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQcU9mRnNHcXZKTnNONUJJcDNaaXp3MkVHUEFVSG1SUkhyYmQwSFhMVjh3RHhUNEJSNDRES3poNG03QThPVHF0dXJBeWJEUjlBbkctWVhCR3RKOHFmaDFyMDNGdTZGdmRzRkxBNlRkRWw4SVhjUUFaNnJUVlM2S3VyZXVwenZMUklGYlF5dUNMSnlwOTdDeW9GNkNiZlJ2eU53YnN3YVNtMUZfZktFZE9HVURTVkJCbDg3NUxVSQ?oc=5","date":"2025-10-30","type":"pipeline","source":"Seeking Alpha","summary":"Apogee Therapeutics: Plan To Take Standard-Of-Care Status From Dupixent Is Risky (APGE) - Seeking Alpha","headline":"Apogee Therapeutics: Plan To Take Standard-Of-Care Status From Dupixent Is Risky (APGE)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTFBPV2t3Rnh4WEoxZGxFNDRCb2sxN1RYdTJqX05vWTBIb2FlbWdaWnJ2VGkwaTBKZkJ0TkJFM1NQcWJEdGdrdlAtTWhYMTZkTFE2MG9ZZ3BzTkU0TkhEdFd4MlRMTFdHWTkzeEpTUVRzNmhIT3VwSndSNHpnSkV0UVk?oc=5","date":"2025-07-07","type":"pipeline","source":"Investor's Business Daily","summary":"How This Small Biotech Is Looking To Take On Sanofi's Cash Cow - Investor's Business Daily","headline":"How This Small Biotech Is Looking To Take On Sanofi's Cash Cow - Investor's Business Daily","sentiment":"neutral"}],"patents":[{"drugName":"APGE-101","drugSlug":"generic-name-not-publicly-disclosed","patentNumber":"","type":"Patent Cliff","expiryDate":"2031-06-01","territory":"US","annualRevenue":1200000000},{"drugName":"APGE-102","drugSlug":"generic-name-not-publicly-disclosed","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":2500000000}],"drugCount":2,"phaseCounts":{"phase_2":1,"phase_1":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Biogen","Roche","Sanofi"],"therapeuticFocus":["Autoimmune Diseases","Immunology"],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":214712000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-255843000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":131549000,"cashHistory":[],"totalAssets":937134000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}